CTA’s Rapid Expansion: Observations from SCCT 2021

Progress is not in enhancing what is, but in advancing toward what will be.

– Kahlil Gibran

Reviewing the recently completed SCCT 2021, the virtual-only annual scientific meeting hosted by the Society for Cardiovascular Computed Tomography(SCCT), was both a personal and professional pleasure. The content across two packed days provided abundant evidence of the increasing role coronary CTA is playing in the cardiovascular care pathway for patients with known or suspected coronary artery disease (CAD) today.

Some of that growth is attributable to rapid technological advances in cardiac CT that are enabling clinicians to non-invasively gather information that can be directly applied to outcome-influencing treatment decisions. Hardware advancements, such as systems now delivering “ultra-high resolution CT,” are an example of improving tools that allow clinicians to visualize important clinical details only suspected or inferred by other non-invasive tests in the past.

The discussions during SCCT 2021, however, made it clear that clinical centers can expand the role of their cardiac CT programs through accessible software and AI solutions to expand the utility and value of coronary CTA. These solutions include tools to simplify and streamline anatomic findings of plaque and stenosis severity throughout the coronary tree or to assess non-invasively the physiologic impact of CAD via FFRCT. As they looked forward, the leaders in the field spoke of how the use of artificial intelligence (AI) will aid clinicians in identifying high-risk CAD and, once evidence of impact on outcomes is obtained, allow optimized management.

Another area of growth has been the marked increase in clinical research involving coronary CTA. As noted by Dr. Todd Villines, editor-in-chief of the Journal of Cardiovascular CT (JCCT), the 12 months from July 2020 to July 2021 have seen the release of approximately 9,000 clinical publications involving coronary CTA, bringing the historical total to nearly 100,000 publications. This encapsulates a wide range of publications ranging from individual anomalous case reviews to large randomized controlled trials, and the sheer volume speaks to the central focus on coronary CTA that has emerged within the research community.

While it is exciting to see the clinical evidence build beyond what is available for any other non-invasive cardiac test, the growing ways in which patients are being served by coronary CTA is even more striking. Of the outstanding data presentations, some stood out as they spoke to the expansion of a CT+FFRCT pathway. For example:

Clinical data released at the SCCT meeting reinforces a refrain from ACC.21 that the anticipated ACC/AHA Practice Guidelines for the Evaluation and Diagnosis of Chest Pain should elevate coronary CTA as a frontline test for patients with suspected CAD. As Dr. Ron Blankstein from Brigham and Women’s Hospital and immediate-past president of the SCCT observed, these clinical guidelines provide an opportunity to guide selection of the most appropriate diagnostic modality and to highlight how imaging findings can inform therapy.

SCCT 2021 reminded us how the clinical data are evermore irrefutable that for non-ACS patients with symptoms suggestive of CAD, coronary CTA is the path to optimally informed treatment and improved long-term outcomes as compared to other available options.

— A perspective from HeartFlow Chief Medical Officer, Campbell Rogers, MD
Bio | LinkedIn

Contact Us

*Required fields

Request the HeartFlow Analysis Near You

If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.

*Required fields

残念ながら、GDPR 規制により、この Web フォームを通じて求人への応募やキャリアに関する問い合わせを受け付けることはできません。弊社を通じてお申込みください 採用ページ. ご関心をお寄せいただきありがとうございます!


HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用​​することを目的としています。


さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.

The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.

For additional indication information about the HeartFlow Analysis, please visit www.heartflow.com/indications.

If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.

Please apply for research grants through our online submission form.

Unfortunately, we cannot take job applications or career inquiries through this web form due to GDPR regulations. Please apply through our Careers Page. Thank you for your interest!

Campbell Rogers, M.D., F.A.C.C.

Executive Vice President and Chief Medical Officer

Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.

He received his A.B. from Harvard College and his M.D. from Harvard Medical School.